Breast cancer protein study in different subtypes
Part of Cancer, Skin clinical trials.
This trial takes a close look at the proteins inside breast cancer cells, using samples from people with different subtypes. It aims to better understand how each type behaves, which could help guide future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have breast cancer, confirmed by a tissue sample (biopsy).
- Your cancer should be either early stage (eBC) or newly metastatic (dnMBC).
- You have not yet started any treatment for this breast cancer.
- You are 18 years or older.
- You are in reasonable health (ECOG score 0–2, meaning you can do daily activities).
- You are covered by French Social Health Insurance.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at tumor “clues” by using tissue and blood samples in people with metastatic breast cancer (with specific subtype). It aims to better understand what drives the cancer, which may help guide future treatments.
This study helps doctors use more individualized (precision) treatment choices for people with certain advanced cancers. You may be offered study care based on your cancer details, aiming to improve treatment decisions.
This trial studies your tumor’s gene activity and breast cancer subtype to help guide treatment choices. It mainly looks at whether analyzing “RNA expression” and tumor subtype can improve how therapy is optimized during metastatic breast cancer care.
This trial looks at breast cancer “proteins” and molecular features using tumor samples taken during surgery or biopsy. The goal is to better understand why breast cancers behave differently, which may help guide more personalized treatment in the future.
This study looks at how breast cancer cells change during chemotherapy and immunotherapy before surgery. By analyzing tumor samples taken during treatment, doctors hope to find early signs of whether the treatment is working, which could lead to better-personalized care for people with triple negative or high-risk luminal breast cancer.
This study looks at the genetic details of HER2-positive breast cancer to help find subtypes and improve future treatments. It does not test a new drug but collects information from your tumor tissue to learn more about the disease.
Hear when a new Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.